Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor.

Ikeda H, Lethé B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG.

Immunity. 1997 Feb;6(2):199-208.

2.

Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection.

Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T, Coulie PG.

Eur J Immunol. 1995 Feb;25(2):340-7.

PMID:
7875194
3.

Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene.

Chiari R, Foury F, De Plaen E, Baurain JF, Thonnard J, Coulie PG.

Cancer Res. 1999 Nov 15;59(22):5785-92.

4.
6.

Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.

Bernhard H, Jäger E, Maeurer MJ, Meyer zum Büschenfelde KH, Knuth A.

Tissue Antigens. 1996 Jul;48(1):22-31.

PMID:
8864171
7.

Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL).

Wölfel T, Hauer M, Klehmann E, Brichard V, Ackermann B, Knuth A, Boon T, Meyer Zum Büschenfelde KH.

Int J Cancer. 1993 Sep 9;55(2):237-44.

PMID:
7690346
9.

A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes.

Brichard VG, Herman J, Van Pel A, Wildmann C, Gaugler B, Wölfel T, Boon T, Lethé B.

Eur J Immunol. 1996 Jan;26(1):224-30.

PMID:
8566071
11.
12.

Antitumor immunity at work in a melanoma patient.

Coulie PG, Ikeda H, Baurain JF, Chiari R.

Adv Cancer Res. 1999;76:213-42. Review.

PMID:
10218103
14.

Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.

Valmori D, Liénard D, Waanders G, Rimoldi D, Cerottini JC, Romero P.

Cancer Res. 1997 Feb 15;57(4):735-41.

15.

Cytotoxic T cell lines recognize autologous and allogeneic melanomas with shared or cross-reactive HLA-A.

Hayashi Y, Hoon DS, Park MS, Terasaki PI, Morton DL.

Cancer Immunol Immunother. 1992;34(6):419-23.

PMID:
1373343
16.

Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.

Slingluff CL Jr, Colella TA, Thompson L, Graham DD, Skipper JC, Caldwell J, Brinckerhoff L, Kittlesen DJ, Deacon DH, Oei C, Harthun NL, Huczko EL, Hunt DF, Darrow TL, Engelhard VH.

Cancer Immunol Immunother. 2000 Mar;48(12):661-72.

PMID:
10752474
17.

Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines.

Kirkin AF, Petersen TR, Olsen AC, Li L, thor Straten P, Zeuthen J.

Cancer Immunol Immunother. 1995 Aug;41(2):71-81.

PMID:
7656272
18.

Control of self-reactive cytotoxic T lymphocytes expressing gamma delta T cell receptors by natural killer inhibitory receptors.

Halary F, Peyrat MA, Champagne E, Lopez-Botet M, Moretta A, Moretta L, Vié H, Fournié JJ, Bonneville M.

Eur J Immunol. 1997 Nov;27(11):2812-21.

PMID:
9394804
19.

Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy.

Kan-Mitchell J, Huang XQ, Steinman L, Oksenberg JR, Harel W, Parker JW, Goedegebuure PS, Darrow TL, Mitchell MS.

Cancer Immunol Immunother. 1993 Jul;37(1):15-25.

PMID:
8513449
20.

Supplemental Content

Support Center